2nd patient death reported in Keytruda combo study

[cesces]

davoceticept is being investigated for prostate cancer

Alpine bails on phase 1 cancer asset after 2nd patient death reported in Keytruda combo study | Fierce Biotech

fiercebiotech.com/biotech/a...

After a second patient death, Alpine Immune Sciences is terminating enrollment for two trials assessing its cancer asset davoceticept, including the biotech’s combo study with Merck’s Keytruda for adults with advanced malignancies.

[GAdrummer]

One death is an anomaly. Two is a trend. Alpine had to stop the studies. Keytruda patients have to be very closely monitored for its dangerous side effects even many months after the treatments cease. Yesterday our MO reminded us that we nearly lost my husband this summer nine months after stopping Keytruda, *because he was hiding his symptoms from me and not reporting them to any of his doctors*!

[Seasid in reply to GAdrummer]

i also don't like to talk about my symptoms. I know it is not good.